MetaCap

Biofrontera (BFRI) vs CytoMed Therapeutics (GDTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biofrontera (BFRI) has outperformed CytoMed Therapeutics (GDTC) over the past year, losing 28.4% versus a loss of 59.8%. Biofrontera is the larger company by market cap ($9.5 million vs $9.0 million), about 1.1 times the size, while CytoMed Therapeutics is growing revenue faster (+395.9% vs +11.7%). Biofrontera converts more of its revenue into profit, with a net margin of -25.3% versus -1227.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BFRI-28.38%GDTC-59.84%
+127%+28%-70%
Nov 21, 20251 yearNov 20, 2026
BFRI-95.55%GDTC-81.13%
+28%-37%-101%
Apr 10, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BFRI versus GDTC key metrics
MetricBFRIGDTC
Share price$0.53$0.755
Market cap$9.51M$9.01M
1-day change-7.02%-2.33%
YTD return-7.02%-43.45%
1-year return-28.38%-59.84%
5-year return-99.66%—
Forward P/E1.32—
EPS (TTM)$-0.26$-0.23
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.70M$252.26K
Revenue growth (YoY)+11.75%+395.88%
Net income (latest FY)$-10.54M$-3.10M
Operating margin-27.21%—
Net margin-25.26%-1227.07%
52-week high$1.66$2.12
52-week low$0.53$0.68
Distance from 52-week high-68.07%-64.39%
Analyst consensusnonenone
Avg. price target upside+1032.08%+450.99%
Average volume429.04K15.69K
Shares outstanding17.95M11.93M
Employees8442
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BFRI has outperformed GDTC by 31.5 percentage points over the past year.
  • Biofrontera is more profitable, keeping -25.3 cents of every revenue dollar as net income versus -1227.1 cents for CytoMed Therapeutics.
  • CytoMed Therapeutics grew revenue faster in its latest fiscal year (+395.88% vs +11.75%).

About Biofrontera

BFRI stock →

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

About CytoMed Therapeutics

GDTC stock →

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.

Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees

BFRI vs GDTC FAQ

Which is bigger, Biofrontera or CytoMed Therapeutics?

Biofrontera (BFRI) is larger, with a market capitalization of $9.51M compared with $9.01M for CytoMed Therapeutics (GDTC).

Which stock has performed better over the past year, BFRI or GDTC?

BFRI returned -28.38% over the past 12 months, compared with -59.84% for GDTC (price return, excluding dividends). Past performance does not predict future results.

Are Biofrontera and CytoMed Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons